Introduction
============

Stroke is a leading cause of morbidity and mortality.[@b1-jpr-6-705] In Europe, the annual standardized incidence of stroke is 113 per 100,000.[@b2-jpr-6-705] Currently, the clinical burden of stroke and transient ischemic attack exceeds that of coronary heart disease.[@b3-jpr-6-705] Recently, Sacco et al found that the annual incidence rates standardized to the Italian population ranged from 175 to 360 per 100,000 in men and from 130 to 273 per 100,000 in women, with 67%--82.6% being ischemic strokes.[@b4-jpr-6-705]

Patients with stroke may suffer several types of pain, including articular pain, musculoskeletal pain, painful spasticity, headache, and neuropathic central post-stroke pain (CPSP). Central post-stroke pain is one of a group of chronic pain conditions that are termed central neuropathic pain, because pain is due to a lesion or a disease affecting the central somatosensory system. Central neuropathic pain may be caused by different pathologic conditions affecting the central somatosensory system, including ischemic and hemorrhagic vascular lesions (eg, CPSP), tumors, trauma, surgical injury, and thalamic arteriovenous malformations.[@b5-jpr-6-705] In the past, CPSP was attributed to a thalamic lesion and known as Dejerine and Roussy syndrome, but is now also associated with extrathalamic lesions because the symptoms and severity of CPSP in thalamic versus extrathalamic stroke do not differ.[@b6-jpr-6-705]

According to the new definition of neuropathic pain,[@b7-jpr-6-705] CPSP is defined as "pain arising as a direct consequence of a cerebrovascular lesion of the somatosensory system in the central nervous system".[@b8-jpr-6-705] The diagnosis of CPSP is challenging, and is often one of exclusion because there are no pathognomonic features or uniform signs, except neurologic damage, and the characteristics and descriptions of CPSP vary substantially between patients.[@b8-jpr-6-705] It has been suggested that the diagnosis should be based on a combination of clinical history and radiologic evaluation in order to recognize the lesion (type, location, and size) and to exclude other possible central causes of pain.[@b6-jpr-6-705]

Damage to the central nervous system (CNS) may result in motor and/or sensory deficits, (as ipo/anesthesia), accompanied by positive neurologic symptoms (thermal and/or mechanical allodinia/hyperalgesia, paresthesias) and intractable pain, which may be characterized by spontaneous and/or evoked pain with or without associated dysesthesia and/or paresthesia.[@b9-jpr-6-705] Data in the literature suggest that age, gender, and side of the lesion in the CNS could not be considered predictors of CPSP.[@b6-jpr-6-705],[@b10-jpr-6-705],[@b11-jpr-6-705]

Although the literature indicates that chronic pain after a stroke is a common condition, its incidence is highly variable (8%--46%),[@b12-jpr-6-705]--[@b14-jpr-6-705] while the prevalence of CPSP has been estimated to be 1%--12%.[@b10-jpr-6-705],[@b12-jpr-6-705],[@b14-jpr-6-705]--[@b17-jpr-6-705]

Most of the literature also classifies skeleton muscular syndromes as post-stroke pain. The prevalence of pain is reported to be as high as 35%--60% in these syndromes, which are secondary to motor dysfunction and/or ankylosis, and pain is mainly of the nociceptive type.

Hansen et al recently investigated the incidence of all common pain types following stroke in a prospective study using 3-month and 6-month follow-up interviews.[@b18-jpr-6-705] At the 6-month follow-up, newly developed pain was reported by 45.8% of the patients (headache by 13.1%, shoulder pain by 16.4%, other joint pain by 11.7%, other pain by 20.0%, and pain evoked by light touch or thermal stimuli by 8.0%). Further, 10.5% of the patients were classified as having possible CPSP and 33.6% of the patients with newly developed pain reported a moderate to severe impact on daily life.

The great complexity of clinical features generates difficulty in clinical evaluation.[@b19-jpr-6-705] Moreover, there are no bio-markers that can discriminate between central and peripheral disnociceptive factors. A critical element, which may be a source of bias in the literature, is the timing of clinical evaluations, that influence the outcome of the investigation, since CPSP does not have an established onset time and possible intervals may have such wide ranges (from days up to 10 years) that the investigations must absolutely take into account the timing of the study.

Klit et al published a population-based study on pain following stroke and included a control group.[@b13-jpr-6-705] The authors reported that development of new onset chronic pain was reported by 39.0% of stroke patients and 28.9% of reference subjects. Jönsson et al reported the prevalence, intensity, and temporal evolution of pain in an unselected group of stroke survivors; they estimated that after 16 months, about 21% of patients suffered from moderate to severe pain.[@b14-jpr-6-705] The burden of this pathologic condition includes not only pain symptoms and positive/negative neurologic sensations, but also their severe impact on quality of life for patients.

In stroke survivors, several factors other than pain may influence quality of life, such as motor impairment, loss of work, depression,[@b20-jpr-6-705],[@b21-jpr-6-705] loss of sleep and appetite, poor social interaction, and disability,[@b22-jpr-6-705] which may impair activities of daily living and worsen quality of life, negatively influencing the rehabilitation process.[@b23-jpr-6-705]

The primary objective of our population-based study was to identify, by telephone interview, the prevalence of CPSP in patients who had had a stroke and were hospitalized for the acute event in district hospitals in Rimini between 2008 and 2010. The secondary objective was to evaluate the type of pain complained of and the efficacy of analgesic treatments received by patients. We selected a limited time interval to evaluate development of pain; this decision had the specific aim of identifying clinical features that can guide attention from all the specialists involved in the patient's care and prevent misinterpretation of early clinical signs and symptoms.

Materials and methods
=====================

We undertook a retrospective, population-based study of the prevalence of CPSP in Rimini district, Italy. The study was approved by the local institutional review board and was conducted in accordance with the Declaration of Helsinki. We collected data from all patients who had had an ischemic stroke and were hospitalized in Rimini district (Rimini, Riccione, Cattolica, Santarcangelo, and Novafeltria hospitals) for the acute event in the period between 2008 and 2010. Stroke patients were identified by careful review of discharge diagnoses and imaging data (confirming the ischemic lesion in the CNS) obtained during hospitalization by a dedicated health care professional.

Rimini district has a population of 329,970. Stroke was diagnosed according to the World Health Organization (WHO) International Classification of Diseases 10th revision criteria (ICD-10). We used data only from patients who were admitted in our health district, which is characterized by a very homogeneous population, by a well structured model of assessment, diagnosis, and therapy, and has the possibility to count on a multidisciplinary task force of physicians specialized in the management of stroke.

Data collection
---------------

Analysis of medical charts enabled us to collect: demographic data; date of the stroke episode; clinical presentation of the stroke episode (describing the presence of neurologic comorbidities or other disorders; and motor and sensory deficits, ie, palsy, hemiparesis, aphasia, and dysarthria). We excluded patients with a past medical history of any persistent pain syndrome from the interview. Data on the prevalence of CPSP were collected by telephone interview performed at least 12 months after the stroke episode (range 12--36 months).

All patients reporting a pain state at the time of the telephone call were then interviewed in more depth, taking into account the following items using an ad hoc questionnaire:

-   date of CPSP onset (at or after the time of stroke onset)

-   pain intensity, using an 11-point visual analog scale (VAS) defining pain as mild (1--3), moderate (4--6), or severe (\>7)

-   pain distribution and characteristics (offering predefined descriptors to be chosen by the patient from a list)

-   features of any neurologic sensory disturbances described by the patient (such as allodynia/paresthesia, dysesthesia)

-   disability and impact of pain on physiologic functions, such as quality of sleep (sleep-wake mechanism) and self or assisted feeding

-   treatment prescribed and efficacy/safety outcomes

-   number and type of medications (nonsteroidal anti-inflammatory drugs and/or acetaminophen, opioids, anticonvulsants, others) prescribed for pain control

-   adverse events due to analgesic drugs (such as nausea, vomiting, dizziness, sedation)

-   quality of life, using the Short Form-12 (SF-12) questionnaire.[@b18-jpr-6-705]

Patients with cognitive impairment were excluded as were those with aphasia/dyslexia, even if low grade, those undergoing treatment with sedatives or major antipsychotic drugs, and those with epilepsy.

All patients whose answers suggested possible CPSP were asked to come to a consultation with a pain specialist. The diagnosis of CPSP was supported by clinical history, imaging data confirming an ischemic lesion in the CNS, pain onset and characteristics, pain located in an area of the body corresponding to the lesion in the CNS, and a clinical and neurologic investigation (bedside sensory examination).

Statistical analysis
--------------------

Continuous data were reported as the mean and ± standard deviation and analyzed using the analysis of covariance model. Statistical significance was defined as *P* \< 0.05. Proportions were expressed as percentages.

Results
=======

Throughout 24 months (2008--2010) we identified 1,494 patients who had had an ischemic stroke in the Rimini district, 322 of whom were deceased by the time of the telephone interview, 36 did not give their consent to participate in the study, and 535 were not contactable by telephone ([Figure 1](#f1-jpr-6-705){ref-type="fig"}). We were able to contact 601 subjects, comprising 327 (54.4%) males and 274 (45.6%) females. The average age of those interviewed was 76.1 ± 10.2 (range 44--96) years. Sixty-six (11%) patients suffered from CPSP, and comprised 38 males (11.6% of total males) and 28 females (10.2% of total females, [Table 1](#t1-jpr-6-705){ref-type="table"}). On stratification of patients complaining of pain according to age, four patients (6%) were aged 40--59 years, 32 (48.5%) were aged 60--79 years, 27 (40.9%) were aged 80--89 years, and three (4.5%) were aged \>90 years. The majority of the patients reported moderate pain (43.9%), whereas 30.3% reported severe pain and 16.7% reported mild pain ([Table 2](#t2-jpr-6-705){ref-type="table"}). When asked about the timing of pain onset, 57.6% reported that their pain had started immediately after the stroke event, 19.7% after a month, and 19.7% after several months ([Table 2](#t2-jpr-6-705){ref-type="table"}). Pain was continuous in 59.6% of patients and intermittent in 36.5% ([Table 2](#t2-jpr-6-705){ref-type="table"}). Features of pain as reported by patients are listed in [Table 3](#t3-jpr-6-705){ref-type="table"}, which shows that pain perceived as a "needle puncture" was the main feature, described by 40.4% of patients, with 40.4% reporting thermal hyperesthesia and 38.5% reporting tactile hyperesthesia.

Disability
----------

Almost one third (30.3%) of those interviewed reported complete or partial motor palsy distributed in a part of the body ipsilateral to the stroke lesion, whereas 13.6% suffered from motor problems in the contralateral part of the body. Another group of patients (10.6%) were affected by palsy in both lower limbs. Motor impairment persisted until the time of interview. It is interesting to note that 9.1% of these stroke patients did not report any motor impairment immediately after the onset of pathology.

With regard to walking ability, 15.2% of patients were still able to move without problems, but 39.4% were very impaired in their movements, with 43.9% being unable to walk at all. Only 6.1% recovered their working skills fully, 4.5% partially, and 83.3% did not recover these at all ([Table 4](#t4-jpr-6-705){ref-type="table"}).

Pain interference with sleep, daily activities, social life, and quality of life
--------------------------------------------------------------------------------

Half (50%) of the interviewed pain population could sleep in a restful way, 28.8% had some difficulty, and 21.8% could not sleep at all ([Table 4](#t4-jpr-6-705){ref-type="table"}). With regard to functional recovery, especially self-care and social life, we found that most of the stroke patients did not recover these abilities. One third (33.3%) could take care of themselves as before the stroke event, 13.6% partially, and 50% not at all. With regard to social life, 36.4% reported good relationships as in the past, 12.1% partially recovered, and 48.5% had lost most of their social relationships, mainly as a result of their motor impairment and inability to leave home ([Table 4](#t4-jpr-6-705){ref-type="table"}). Quality of life was assessed using the SF-12 questionnaire, the results of which showed a mean physical component summary of 30.77 ± 8.47 and a mental component summary of 37.93 ± 8.64. These values were significantly (*P* \< 0.05) lower than the average physical component summary of 51.2 ± 7.4 and mental component summary of 47.8 ± 10.1 reported by Gandek et al for the Italian population.[@b24-jpr-6-705]

Pain treatments
---------------

In total, 43.3% of patients with pain were prescribed analgesic/anti-inflammatory drugs, 10.1% pregabalin, 4.8% opioids, 5.5% other drugs (including muscle relaxants and homeopathic or natural approaches), and 29.3% were not prescribed any analgesic therapy ([Table 5](#t5-jpr-6-705){ref-type="table"}). Analgesics were prescribed immediately after the stroke episode in 36.7% of patients and some months later in 56.6% of cases, with 6.7% of patients receiving analgesics on an as-needed basis.

Discussion
==========

CPSP has been underestimated for years, but nowadays is receiving wider interest. CPSP can develop immediately or up to 10 years after the stroke event, but usually develops 3--6 months after the stroke.[@b11-jpr-6-705],[@b25-jpr-6-705] Jönsson et al found that one third of patients complained of moderate to severe pain 4 months after stroke onset, and that 20% were still experiencing moderate to severe pain with increasing intensity one year later.[@b14-jpr-6-705]

These findings suggest that a long follow-up period is necessary to evaluate CPSP,[@b19-jpr-6-705] because pain may occur months or years after a stroke, and this may be due to the complex nature of post-stroke pain. Further, the clinical trial data underscore how difficult it is to treat this syndrome effectively.

The results of our study show a CPSP prevalence of 11%, with no "gender" effect. This prevalence is within the range reported in the literature (1%--12%).[@b8-jpr-6-705],[@b12-jpr-6-705],[@b17-jpr-6-705] With regard to pain characteristics, consistent with the data in the literature, we found that tactile and thermal hyperesthesia were the most commonly described features, accompanied by sensations of "needle puncture", tingling, swelling, and pressure. In our sample, pain intensity was mainly moderate to severe and again, in accordance with the literature, was mainly continuous. However, in contrast with the published data, we found that the pain had started in the first month after the lesion in the majority of patients.

Location of the pain was variable, but hemisyndrome or lower limb involvement was frequent, resulting in motor impairment and disability affecting social relationships and causing sleep disturbance, in concordance with previous studies.[@b8-jpr-6-705] The majority of patients were treated with analgesic/anti-inflammatory drugs and anticonvulsants (pregabalin). This is in agreement with the study by Zorowitz et al, which reported that the most frequently prescribed pain medications for CPSP were analgesics, mainly acetaminophen and tramadol, followed by anticonvulsant.[@b26-jpr-6-705] Use of pregabalin for treatment of central chronic pain[@b27-jpr-6-705] and in particular of CPSP has been reported previously.[@b28-jpr-6-705],[@b29-jpr-6-705] Alarmingly, 29.3% of our sample did not receive any analgesic treatment despite being in pain.

It is well established that quality of life is impaired in patients with mild to moderate deficits after brain infarction.[@b30-jpr-6-705] Our results applying the SF-12 questionnaire, in accordance, showed scores lower than 50 in both the mental and physical domains and were statistically lower than for the average Italian population.[@b24-jpr-6-705] This deterioration of patients' self-perceived physical and mental function is in agreement with previous studies.[@b31-jpr-6-705],[@b32-jpr-6-705]

Our survey has the limitations common to all observational studies, including the limited geographic area covered. However, it can be seen as a pilot study for more detailed data collection, because further studies are necessary to address this issue. Despite the limitations of this study, we found a CPSP prevalence rate of 11%, which is superimposable on the data reported in the literature and, interestingly, about 30% of these patients did not receive any treatment.

Conclusion
==========

Our study found that the prevalence of CPSP was as high as 11%, with a consequent serious social and economic impact. In the majority of cases, pain appeared in the first month after the stroke, but there was a significant proportion of patients who developed pain several months after the event. Further, a high proportion of patients were not receiving treatment for their pain despite complaining of it, or were receiving an inappropriate treatment. Hence we believe that it is necessary to implement a campaign to educate physicians, including neurologists, who, in most cases, do not consider pain to be an important concern in stroke patients. Moreover, the issue of appropriate treatment of CPSP should be recognized as a challenge and addressed in further studies.
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###### 

Characteristics of patients referring central post-stroke pain

  --------------------------------------------- ---------------
  Patients referring CPSP/interviewed pts (%)   66/601 (11)
  Male (%)                                      38/327 (11.6)
  Female (%)                                    28/274 (10.2)
  Average age (years)                           76.1 ± 10.2
  Age range (years)                             44--96
  Average Vas score                             5.8 ± 2.5
  --------------------------------------------- ---------------

**Abbreviations:** CPSP, central post-stroke pain; VAS, visual analog scale; pts, patients.

###### 

CPSP characteristics

                               n    \%
  ---------------------------- ---- ------
  Pain intensity (VAS scale)        
   Mild (1--3)                 11   16.7
   Moderate (4--7)             29   43.9
   Severe (8--10)              20   30.3
   Not defined by patient      6    9.1
  Pain location                     
   All limbs                   5    7.6
   Inferior limbs              12   18.2
   Superior limbs              6    9.1
   Half-body                   13   19.7
   Hand                        13   19.7
   Shoulder                    3    4.5
   Other                       6    9.1
   Not defined by patient      8    12.1
  Pain onset                        
   Immediately                 38   57.6
   After a month               13   19.7
   After several months        13   19.7
   Not defined by patient      2    3
  Pain temporal pattern             
   Continuous                  39   59.2
   Intermittent                24   36.3
   Not defined by patient      3    4.5

**Abbreviations:** CPSP, central post-stroke pain; VAS, visual analog scale.

###### 

Pain descriptors and sensory disturbance reported by patients

  Pain features           Yes   No     Not defined              
  ----------------------- ----- ------ ------------- ------ --- -----
  Tactile hyperesthesia   20    38.5   30            57.7   2   3.8
  Thermal hyperesthesia   21    40.4   28            53.8   3   5.8
  Tingling                18    34.6   31            59.6   3   5.8
  Needle puncture         21    40.4   26            50.0   5   9.6
  Swelling                16    30.8   33            63.5   3   5.8
  Duress                  11    21.2   36            69.2   5   9.6

###### 

Disability and sleep disturbance

                                  Good   Partial   None   Not defined                   
  ------------------------------- ------ --------- ------ ------------- ---- ------ --- -----
  Walking                         10     15.2      26     39.4          29   43.9   1   1.5
  Working skills rehabilitation   4      6.1       3      4.5           55   83.3   3   6.1
  Self care rehabilitation        22     33.3      9      13.6          33   50     2   3
  Social life rehabilitation      32     36.4      8      12.1          24   48.5   2   3
  Sleeping                        33     50        19     28.8          14   21.8   0   0

###### 

Pharmacological treatments prescribed

                                   n    \%
  -------------------------------- ---- ------
  Medications                           
   Analgesic/anti-inflammatory     29   43.3
   None                            18   29.3
   Pregabalin                      7    10.1
   Opioids                         3    4.8
   Other                           4    5.5
   Not defined                     5    7
  Prescribed use of medications         
   Continuous (daily assumption)   12   40
   "As needed" therapy             18   60
